Hollings Cancer population scientist identifies rapid rise in cervical cancer in millennial women 霍林斯癌症人口科學家發現千禧一代女性宮頸癌發病率迅速上升

中文版谷歌中文翻譯(90% 準確率) | English translation
Buy/Sell Your Domains Here。在這裡購買/出售您的域名
Contact Dr. Lu for information about cancer treatments。聯繫盧博士,獲取有關癌症治療資訊。

Why? With medical science so advanced, but our cancer risk is on the rise?  They say after 10 or 15 years, 100% individuals will get a cancer or two during their lifetime.  Right now, 50% of men and one third of women will get it. So our health condition is getting worse and worse? Is it because we get too many vaccines? Why?

為什麼? 醫學如此發達,我們的患癌風險卻在上升? 他們說 10 或 15 年後,100% 的人一生中會患上一兩次癌症。 現在,50% 的男性和三分之一的女性會得到它。 所以我們的健康狀況越來越差了? 是因為我們接種了太多疫苗嗎? 為什麼?

News Release

Increase follows decades of decline

Peer-Reviewed Publication

Medical University of South Carolina

Dr. Ashish Deshmukh
image: Dr. Ashish Deshmukh says the U.S. urgently needs campaigns and innovative ways to improve cervical cancer screening uptake. view more 

Credit: Clif Rhodes/MUSC Hollings Cancer Center

MUSC Hollings Cancer Center researcher Ashish Deshmukh, Ph.D., identified a dramatic recent rise in cervical cancer incidence among women in their early 30s. This work was published Nov. 21 in the Journal of the American Medical Association (JAMA).

Cervical cancer is mostly related to human papillomavirus (HPV), and screening has made this cancer preventable. Yet, it is estimated that over 14,000 new cases will be diagnosed this year and more than 4,000 deaths will be attributed to cervical cancer.

“HPV is a group of over 200 viruses. At least 14 high-risk HPV types can cause several types of cancers, including cervical, anal and head and neck cancers. In the era of the overall decline in cancer incidence, cancers caused by HPV are unfortunately rising,” said Deshmukh, an associate professor in the Department of Public Health Sciences at MUSC.

Deshmukh, who joined Hollings in August as the co-leader of the Cancer Control program, focuses on cancer epidemiology and etiology research, generating an evidence base for cancer prevention and working with stakeholders and policymakers to develop public policy and inform practice.

“In the era of the overall decline in cancer incidence, cancers caused by HPV are unfortunately rising.”

Ashish Deshmukh, Ph.D.
co-leader, Hollings Cancer Control

An expert in the field of HPV-associated malignancies, Deshmukh has followed the cervical cancer incidence rate in the United States for several years. Previously, he found that evidence-based screening recommendations contributed to the decline in cervical cancer since the 1970s. However, starting from 2012, the national rates of cervical cancer incidence have plateaued.

“For the last two years, we have been trying to understand why the continuous decline in cervical cancer stopped in 2012 and why we have reached a critical turning point,” said Deshmukh.

To get a better understanding, Deshmukh and colleagues, including Hollings researcher Kalyani Sonawane, Ph.D., began to dissect cervical cancer incidence by age using the 2001 to 2019 National Program of Cancer Registries (NPCR) and the Surveillance Epidemiology and End Results (SEER) dataset. “This dataset includes cancer incidence data from all 50 states and covers over 98% of the U.S. population. Using five-year age cutoffs, we found that in women age 30 to 34, the declining rate of cervical cancer incidence reversed for the first time,” said Deshmukh.

A 3% per year increase in cervical cancer incidence in women in their early 30s began in 2012. “What’s very surprising is that the rates increased in non-Hispanic White women, Hispanic women and other ethnic groups but not in non-Hispanic Black women,” said Deshmukh.

The researchers’ findings showed an increase in both localized and regional disease, and the incidence increased for both squamous cell cervical carcinoma and cervical adenocarcinoma. Deshmukh said squamous cell carcinoma is largely detected by screening, so the public health policy implication of this finding is that we need to improve screening rates.

Cervical cancer screening rates have dramatically declined in the U.S. recently, particularly among young women age 21-29 years. “It is critically important to determine if the increase in cervical cancer incidence in young women is due to the decrease in screening rates in women age 21 to 29 years or whether it is due to the introduction of more effective HPV testing in recent years. However, we do know that we need future research to understand this problem thoroughly,” said Deshmukh.

The U.S. urgently needs national campaigns and innovative ways to improve cervical cancer screening uptake and adherence among women, Deshmukh said. He plans to continue to study reasons that underlie the recent rise in cervical cancer incidence.

As part of Hollings’ Cancer Control Program, research such as this helps to inform cancer epidemiology and public health policy and raise awareness. As a general guideline, women age 21 to 29 are advised to screen with a Pap smear every three years, and women age 30 to 65 are advised to continue either with a Pap smear every three years or to move to HPV testing or co-testing, which utilizes both a Pap smear and an HPV test every five years. Doctors might recommend routine screening past 65 years if a patient’s previous tests were abnormal.

Promoting HPV vaccinations, along with routine screening, is a crucial strategy to decrease the number of deaths associated with cervical cancer. “Hollings Cancer Center does wonderful work of bringing lifesaving screenings and vaccinations to people across South Carolina. I expect that the HPV vaccination van and mobile health unit that target rural communities to increase vaccination and screening rates in underserved areas will make a difference in South Carolina’s HPV-related cancer burden in the coming decades,” said Deshmukh.

About MUSC Hollings Cancer Center

MUSC Hollings Cancer Center is South Carolina’s only National Cancer Institute-designated cancer center, with the largest academic-based cancer research program in the state. The cancer center comprises more than 120 faculty cancer scientists and 20 academic departments. It has an annual research funding portfolio of more than $44 million and is dedicated to preventing and reducing the cancer burden across South Carolina. Hollings offers state-of-the-art diagnostic capabilities, therapies and surgical techniques within multidisciplinary clinics that include surgeons, medical oncologists, radiation therapists, radiologists, pathologists, psychologists and other specialists equipped for the full range of cancer care, including more than 200 clinical trials across South Carolina. For more information, visit hollingscancercenter.musc.edu.

$$$ If you are interested in a writer or editor position, check out here.We are hiring. $$$


No Responses

Write a response

fifteen + eight =